Replication and immunogenicity of Ad7-, Ad4-, and Ad5-hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees

Vaccine

Volumn 15, Issue 3, 1997, Pages 335-339

  Chengalvala, Murty V ^a   Bhat, Bheem M ^a   Bhat, Ramesh A ^a   Dheer, Surendra K ^a   Lubeck, Michael D ^a   Purcell, Robert H ^b   Murthy, Krishna K ^c  

^a WYETH AYERST RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

adenovirus; animal model; E3 genes; hepatitis B

Indexed keywords

HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; HEPATITIS B; HEPATITIS B VIRUS; IMMUNOGENICITY; INTRANASAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRUS E3 PROTEINS; ADENOVIRUSES, HUMAN; ANIMALS; GENETIC VECTORS; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; PAN TROGLODYTES; RECOMBINANT FUSION PROTEINS; VIRUS REPLICATION;

EID: 0031043415     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00174-0     Document Type: Article

References (24)

1. Szmuness, W. Hepatocellular carcinoma and the hepatitis B virus: evidence for a casual association. Prog. Med. Virol. 1978, 24, 40-69
2. Ellis, R.W. New and improved vaccines against hepatitis B. In: New Generation Vaccines (Eds Woodrow, G. and Levine, M.). Marcel Dekker, New York, 1990, pp. 439-447
3. Berkner, K.L. Development of adenovirus vectors for gene expression of heterologous genes. Biotechniques 1988, 6, 616-629
4. Chengalvala, M., Lubeck, M., Selling, B. et al. Adenovirus vectors for gene expression. Curr. Opin. Biotechnol. 1991, 2, 718-722
5. 3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology 1991, 184, 1-8
6. Ballay, A., Levrero, M., Buendia, M.-A., Tiollais, P. and Perricaudet, M. In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human adenoviruses. EMBO JI 1985, 4, 3861-3865
7. Davis, A., Kostek, B., Mason, B. et al. Expression of hepatitis B surface antigen with a recombinant adenovirus. Proc. Natl Acad. Sci. U.S.A. 1985, 82, 7560-7564
8. Schaffhausen, B.S., Bockus, B.J., Berkner, K.L., Kaplan, D. and Roberts, T.M. Characterization of middle T antigen expressed by using an adenovirus expression system. J. Virol. 1987, 61, 1221-1225
9. Dewar, R.L., Natarajan, V., Vasudevachari, M.B. and Salzman, N.P. Synthesis and processing of human immunodeficiency virus type 1 envelope proteins encoded by a recombinant human adenovirus. J. Virol. 1989, 63, 129-136
10. Berkner, K.L., Schaffhausen, B.S., Roberts, T.M. and Sharp, P.A. Abundant expression of polyomavirus middle T antigen and dihydrofolate reductase in an adenovirus recombinant. J. Virol. 1987, 61, 1213-1220
11. Top, F.H., Buescher, E.L., Bancroft, W.H. and Russell, P.K. Immunization with live types 7 and 4 adenovirus vaccines II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J. Infect. Dis. 1971, 124, 155-160
12. Horwitz, M.S. Adenoviruses. In: Virology (Eds Fields, B.N. and Knipe, D.M.). Raven Press, New York, 1990, pp. 1723-1740
13. Lubeck, M.D., Davis, A.R., Chengalvala, M. et al. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc. Natl Acad. Sci. U.S.A. 1989, 86, 6763-6767
14. Natuk, R.J., Lubeck, M.D., Chanda, P.K. et al. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res. Human Retroviruses 1993, 9, 395-404
15. Levrero, M., Barban, V., Manteca, S. et al. Defective and non defective adenovirus vectors for expressing foreign genes in vitro and in vivo. Gene 1991, 101, 195-202
16. 3) in pathogenesis of adenovirus disease. Proc. Natl Acad. Sci. U.S.A. 1989, 86, 3823-3827
17. Adrian, T., Best, B., Hierholer, J.C. and Wigand, R. Molecular epidemiology and restriction site mapping of adenovirus type 3 genome types. J. Clin. Microbiol. 1989, 27, 1329-1334
18. Adrian, T., Beckner, M., Hierholer, J.C. and Wigand, R. Molecular epidemiology and restriction site mapping of adenovirus 7 genome types. Arch. Virol. 1989, 106, 73-84
19. Chengalvala, M., Bhat, B.M., Bhat, R. et al. Immunogenicity of high expression adenovirus-hepatitis B virus recombinant vaccines in dogs. J. Gen. Virol. 1994, 75, 125-131
20. 3/19k protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigen. Proc. Natl Acad. Sci. U.S.A. 1987, 84, 1356-1360
21. 3 14.7 kd protein, an antagonist of tumor necrosis factor cytolysis, increases the virulence of vaccinia virus in severe combined immunodeficient mice. Proc. Natl Acad. Sci. U.S.A. 1994, 91, 10987-10991
22. 3 region of adenovirus. Cell 1989, 57, 135-144
23. 3 of adenovirus. J. Virol. 1991, 65, 3095-3105
24. Tacket, C.O., Losonsky, G., Lubeck, M.D. et al. Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. Vaccine 1992, 10, 673-676